End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
-.--% | -.--% |
Sales 2024 * | 15Cr 1.21TCr | Sales 2025 * | 27Cr 2.25TCr | Capitalization | 104.09Cr 8.69TCr |
---|---|---|---|---|---|
Net income 2024 * | -14Cr -1.17TCr | Net income 2025 * | -5.1Cr -425.59Cr | EV / Sales 2024 * | 6.19 x |
Net cash position 2024 * | 14Cr 1.18TCr | Net cash position 2025 * | 11Cr 956.67Cr | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-7.27
x | P/E ratio 2025 * |
-20.3
x | Employees | 244 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.91% |
Latest transcript on Tarsus Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 01/17/01 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 24/23/24 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 16/20/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 01/17/01 |
Wendy Yarno
BRD | Director/Board Member | 68 | 19/20/19 |
Director/Board Member | 69 | 01/19/01 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.55% | 82TCr | |
+42.31% | 64TCr | |
-6.83% | 35TCr | |
+17.15% | 32TCr | |
+7.09% | 30TCr | |
+14.02% | 24TCr | |
+1.64% | 22TCr | |
+13.66% | 22TCr | |
+7.87% | 17TCr |